Once a community and an individual begin annual Mectizan® treatment, they continue 'forever'.
Endemicity of Onchocerciasis
High Figure 1 ). RAPLOA-40 RAPLOA-20 Probability of community testing RAPLOA-positive in which no one has L. loa microfilaremia of >30,000 per ml (1 -specificity) 5% 50%
Probability of community testing RAPLOA-positive in which 0 -0.9% of persons have L. loa microfilaremia of >30,000 per ml 50% 100%
Probability of community testing RAPLOA-positive in which 1 -1.9% of persons have L. loa microfilaremia of >30,000 per ml 70% 100%
Probability of community testing RAPLOA-positive in which ≥2% of persons have L. loa microfilaremia of >30,000 per ml 100% 100%
Sensitivity in detecting potentially 'at risk' communities 50 -100% 100% Specificity in detecting potentially 'at risk' communities 95% 50%
Risk of Onchocercal Disease in the Absence of Treatment
Mean lifetime risk of blindness in persons born into and living in areas:
Hyper-endemic for onchocerciasis 25% Meso-endemic for onchocerciasis 5% Hypo-endemic for onchocerciasis 1%
Mean lifetime risk of skin disease in persons born into and living in areas:
Hyper-endemic for onchocerciasis 50% Meso-endemic for onchocerciasis 30% Hypo-endemic for onchocerciasis 15%
Note: these figures would underestimate risk of skin disease in areas where the sowda form of onchocerciasis predominates.
